Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2Hui Wang, Xiaoming Yang, Yuntao Zhang et al.|Cell|2020Cited by 802
Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19Xin Hu, Min Shen, Anton Simeonov et al.|ACS Pharmacology & Translational Science|2021Cited by 56
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variantsJessica Hong, Mitchell Ho, Hyung Joon Kwon et al.|Proceedings of the National Academy of Sciences|2022Cited by 37
Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particlesCatherine Z. Chen, Gary R. Whittaker, Miao Xu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 20
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs <i>in vitro</i>Qi Zhang, Yihong Ye, Catherine Z. Chen et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 13